Therapeutic Effect of Alanylglutamine Combined with Ulinastatin in Patients with Severe Acute Pancreatitis
Objective To explore the therapeutic effect of octreotide combined with ulinastatin in patients with severe acute pancreatitis.Methods 86 patients with severe acute pancreatitis admitted to the Third People's Hospital of Linyi City from January 2020 to December 2022 were selected as the study subjects and randomly divided into a control group and an observation group,with 43 cases in each group.The control group was treated with octreotide,while the observation group was treated with ulinastatin on the basis of the control group.The treatment time was 4 days for both groups.Compare the improvement time,disease severity,inflammatory response,and incidence of adverse reactions related to pancreatitis between two groups.Results After treatment,the Balt-hazar CT score,Acute Physiology and Chronic Health Evaluation-Ⅱ score in the observation group were lower than those in the control group,the high mobility group protein B1,tumor necrosis factor-α,serum interleukin-6 were lower than those of control group,and the time for disappearance of abdominal distension and pain,as well as the time for recovery of bowel sounds and body temperature,were shorter than those in the control group,with statistical significance(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of octreotide and ulinastatin has a significant effect on the treatment of severe acute pancreatitis,which can quickly improve the relevant signs of pancreatitis,reduce the severity of the disease and inflammatory response,and have high safety.
Severe acute pancreatitisUlinastatinOctreotideSeverity of the diseaseInflammatory response
NETL
NSTL
万方数据
